Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Colchicine Clear all
Completed Phase 2 Interventional Results available

Colchicine and CRP in Atrial Fibrillation and AF Ablation

NCT01755949
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Colchicine, 0.6 mg PO BID, Matching placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 25, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)

NCT04130204
View directory record Official record
Conditions
Gout
Interventions
DYV700, Placebo, Colchicine 0.6 mg
Drug
Lead sponsor
Dyve Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Poway, California
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 25, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

NCT00798369
View directory record Official record
Conditions
Acute Gout
Interventions
Canakinumab, Triamcinolone acetonide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Anniston, Alabama • Birmingham, Alabama • Buena Park, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Oct 25, 2026, 1:09 PM EDT
Recruiting Phase 4 Interventional

The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial

NCT05618353
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Colchicine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
9
States / cities
Birmingham, Alabama • Long Beach, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 25, 2026, 1:09 PM EDT
Recruiting Phase 3 Interventional

PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

NCT07232069
View directory record Official record
Conditions
Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control, Premature Atherosclerosis
Interventions
Rosuvastatin 20 Mg Oral Tablet, Colchicine 0.5 MG Oral Tablet Once Daily, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
30 Years to 60 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 25, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients

NCT01399008
View directory record Official record
Conditions
Gout
Interventions
Arhalofenate, Allopurinol, Colchicine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
16
States / cities
Lincoln, California • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 25, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

NCT00819585
View directory record Official record
Conditions
Gout
Interventions
Canakinumab, Colchicine, Allopurinol, Placebo Matching Canakinumab, Placebo Matching Colchicine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 25, 2026, 1:09 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of LOw DOse COlchicine in Patients With STatin INTolerance: the LODOCO STINT Pilot Study

NCT06874192
View directory record Official record
Conditions
Statin Adverse Reaction
Interventions
Low-dose colchicine at 0.5mg daily, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 1:09 PM EDT
Recruiting Phase 4 Interventional

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

NCT04875702
View directory record Official record
Conditions
Gout
Interventions
Allopurinol, Naproxen 250 MG, Colchicine 0.6 mg, Colchicine 1.2 mg, Naproxen 500 Mg, Prednisone 40 mg
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
South Birmingham, Alabama • Santa Monica, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 25, 2026, 1:09 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)

NCT04762771
View directory record Official record
Conditions
Covid19
Interventions
Colchicine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 25, 2026, 1:09 PM EDT
Recruiting Phase 4 Interventional

Colchicine's Effect on Inflammatory Markers

NCT07287345
View directory record Official record
Conditions
Colchicine, Inflammation in Cardiac Surgery, Post Operative Atrial Fibrillation, Inflammatory Markers, Colchicine Adverse Reaction
Interventions
Colchicine (Colcrys®), Placebo
Drug
Lead sponsor
Ayesha Ather
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 25, 2026, 1:09 PM EDT
Recruiting Phase 4 Interventional

Colchicine in Acutely Decompensated HFREF

NCT06286423
View directory record Official record
Conditions
Heart Failure, Decompensated Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions
Colchicine 0.6 mg, Control/Placebo group
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 25, 2026, 1:09 PM EDT
Completed Phase 2 Interventional

Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout

NCT02330796
View directory record Official record
Conditions
Gout
Interventions
Bucillamine, Colchicine
Drug
Lead sponsor
Revive Therapeutics, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
San Roman, California • Arlington, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 25, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)

NCT04355143
View directory record Official record
Conditions
COVID-19
Interventions
Colchicine Tablets, Current care per UCLA treating physicians
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Los Angeles, California • Santa Monica, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 25, 2026, 1:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

MPC-004 for the Treatment of an Acute Gout Flare

NCT00506883
View directory record Official record
Conditions
Gout
Interventions
High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose), Placebo Control
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
83
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 25, 2026, 1:09 PM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

NCT02063997
View directory record Official record
Conditions
Gout
Interventions
Arhalofenate 600 mg, Allopurinol 300 mg, Colchicine 0.6 mg, Placebo, Arhalofenate 800 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
52
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 25, 2026, 1:09 PM EDT
Completed Phase 3 Interventional Results available

Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)

NCT03310125
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Myocardial Injury After Non-Cardiac Surgery
Interventions
Active Colchicine, Active Placebo
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
55 Years and older
Enrollment
3,209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
Weston, Florida • Detroit, Michigan • Stony Brook, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 1:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Anti-platelet Effects of Colchicine in Healthy Volunteers

NCT02140372
View directory record Official record
Conditions
Healthy
Interventions
Colchicine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 25, 2026, 1:09 PM EDT
Completed Phase 3 Interventional Results available

RegoNivo vs Standard of Care Chemotherapy in AGOC

NCT04879368
View directory record Official record
Conditions
Gastro-Oesophageal Cancer
Interventions
Regorafenib, Nivolumab, Docetaxel, Paclitaxel, Irinotecan, Trifluridine/Tipracil
Drug · Biological
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Network
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 25, 2026, 1:09 PM EDT
Active, not recruiting Phase 4 Interventional

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

NCT05850091
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Rosuvastatin, Colchicine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 25, 2026, 1:09 PM EDT
Recruiting Phase 3 Interventional

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

NCT04774159
View directory record Official record
Conditions
Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation
Interventions
Colchicine 0.5 MG Oral Tablet, Colchicine-Placebo
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
6,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
24
States / cities
New Haven, Connecticut • Gainesville, Florida • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 1:09 PM EDT